Genprex Advances Mesothelioma Therapy with NYU Langone

911 Meso Info

911 Meso Info is a dedicated voice in the fight against mesothelioma, committed to raising awareness, providing reliable information, and empowering individuals affected by this rare disease. With a passion for advocacy, 911 Meso Info delivers insightful resources, up-to-date research, and practical tips to help patients and families navigate their mesothelioma journey. From treatment options and legal guidance to emotional support and prevention strategies, 911 Meso Info is your go-to source for comprehensive mesothelioma knowledge. Connect with us to stay informed and find strength in community. Follow 911 Meso Info for trusted advice and support, and join us in spreading awareness for a brighter tomorrow.

News Summary

Genprex, Inc. partners with NYU Langone to advance its gene therapy Reqorsa, targeting malignant pleural mesothelioma, aiming to improve patient outcomes.

Genprex Partners with NYU Langone in Groundbreaking Mesothelioma Therapy Development

In a significant advancement for cancer treatment, Genprex, Inc. (NASDAQ: GNPX) has entered into an exclusive patent license agreement with NYU Langone Health aimed at propelling the development of its innovative gene therapy, Reqorsa. This therapy specifically targets Malignant Pleural Mesothelioma (MPM), a particularly aggressive form of cancer with around 3,000 new cases diagnosed annually in the United States.

Positive Initial Findings for Reqorsa

Reqorsa is showing promise, having demonstrated significant efficacy in preliminary research studies. The collaborative work involved treating MPM cell lines and mesothelial LP9 cells with Reqorsa and standard control liposomes. Utilizing advanced analysis methods such as RT-PCR, Western blot, and various functional assays, researchers found that Reqorsa notably reduced cell proliferation and invasion while promoting apoptosis, or programmed cell death.

At the core of this therapy lies the TUSC2 gene, which has robust tumor-suppressive properties. The successful delivery of this gene through Reqorsa could represent a viable treatment avenue for patients battling MPM. Alarmingly, the expression of the TUSC2 gene is diminished in approximately 84% of mesothelioma cases, indicating a likely target for intervention.

Rising Fatality Rates and Treatment Challenges

As it stands, about 2,500 deaths are attributed to mesothelioma annually in the U.S. The most prevalent form occurs in the pleura, accounting for 80-90% of all mesothelioma cases. Unfortunately, the prognosis for pleural mesothelioma remains grim, with a life expectancy of roughly 18 months, and only a 3-year survival rate of 23% with treatment. This underscores the urgent need for new and effective therapies like Reqorsa to improve patient outcomes.

Investment Potential and Market Response

Genprex’s prospects are creating waves in the investment community. One analyst has set an ambitious one-year price target for Genprex, estimating an average target price of $7.50. Given the company’s current stock price of only $0.28, this translates to a potential upside of a staggering 2,533.43%. The consensus recommendation from brokerage firms also highlights an “Outperform” status, indicating strong optimism surrounding Genprex’s ongoing endeavors.

The Mesothelioma Clinical Advisory Board formed by Genprex in 2024 plays a crucial role by supporting the preclinical oncology program. Comprised of four esteemed researchers from leading institutions specializing in mesothelioma treatment, the board is expected to facilitate the advancement of Reqorsa through its expert insights and comprehensive research knowledge.

Advanced Delivery System Enhances Efficacy

Reqorsa, also known as quaratusugene ozeplasmid, utilizes a revolutionary plasmid therapy encapsulated in non-viral lipid-based nanoparticles. The Oncoprex® Delivery System precisely administers Reqorsa intravenously, enabling it to target negatively charged cancer cells while minimizing the uptake in normal healthy tissues. Laboratory studies at esteemed institutions like MD Anderson reveal that the TUSC2 uptake in tumor cells after treatment with Reqorsa is between 10 to 33 times higher than that in normal cells, bolstering the case for this innovative treatment.

A Vision Beyond Cancer

In addition to its focus on mesothelioma, Genprex is also advancing therapies for diabetes, demonstrating its commitment to addressing multiple serious health challenges. The company’s diabetes gene therapy employs an AAV vector to deliver essential genes to the pancreas, aiming to convert alpha cells into functional beta-like cells for improved insulin production.

Investors and the public interested in staying informed about Genprex’s developments can register for updates through the company’s website and actively follow its announcements on various social media platforms. It’s worth noting that while much excitement surrounds these advancements, the press release includes forward-looking statements that could be subject to various risks and uncertainties.

The successful development of Reqorsa holds the potential to be a pivotal advancement for MPM patients, promising a glimmer of hope in a challenging landscape that has remained stagnant for far too long. As research progresses, many will be watching closely for the next groundbreaking results.